GL Stock Forecast & Price Target

Globe Life is attractive because its core franchise serves an underserved lower-middle and middle-income market through an exclusive distribution model that supports mid-single-digit or better premium growth while keeping underwriting, balance sheet, and market risk below peers. The company’s fundamentals are strengthening through life sales acceleration, health sales momentum, favorable mortality-driven margin expansion, and an assumption update that reduced policy obligations by about $120 million, while investment income and active share repurchases should further support low-double-digit EPS growth. In addition, the Bermuda reinsurance structure is expected to lift excess cash flow and deployable capital over time, yet shares still trade below historical valuation multiples, suggesting the market underappreciates the durability of its growth and capital return profile.

Globe Life is facing a weaker fundamental backdrop as 3Q26 missed expectations and forced 2026E EPS down to $15.49 from $15.75, while 2027E fell to $16.40 amid lower projected Health margins of 21% and slightly lower excess net investment income. The outlook is further pressured by medical claims severity, Medicare supplement claim irregularity, and management’s own 2027 guidance implying only 1%-2% net operating income growth, with 5%-6% of the 7% EPS growth coming from buybacks rather than core operating improvement. That mix suggests earnings quality is deteriorating and the stock’s current valuation already reflects its safer reputation, leaving limited room for upside if claims volatility and margin pressure persist.